Flavin-containing monooxygenase 3 as a potential player in diabetes-associated atherosclerosis

Nature Communications

Volumn 6, Issue , 2015, Pages

  Miao, Ji ^a,j   Ling, Alisha V ^a,f   Manthena, Praveen V ^a   Gearing, Mary E ^a   Graham, Mark J ^b   Crooke, Rosanne M ^b   Croce, Kevin J ^c   Esquejo, Ryan M ^d   Clish, Clary B ^e   Torrecilla, Esther ^f   Vázquez, Gumersindo Fernández ^f   Rubio, Miguel A ^h,i   Cabrerizo, Lucio ^h,i   Barabash, Ana ^h   Pernaute, Andrés Sánchez ^h,i   Torres, Antonio J ^h,i   Vicent, David ^f,g   Biddinger, Sudha B ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b ISIS PHARMACEUTICALS   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d BURNHAM INSTITUTE   (United States)

^e BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^f HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^g HOSPITAL UNIVERSITARIO LA PAZ IDIPAZ   (Spain)

^h HOSPITAL CLÍNICO SAN CARLOS   (Spain)

ⁱ SCHOOL OF MEDICINE   (Spain)

^j HOSPITAL RAMÓN Y CAJAL   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DIMETHYLANILINE MONOOXYGENASE; FLAVIN CONTAINING MONOOXYGENASE 3; INSULIN; STEROL REGULATORY ELEMENT BINDING PROTEIN 2; TRANSCRIPTION FACTOR FKHR; TRIMETHYLAMINE OXIDE; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; DIMETHYLANILINE MONOOXYGENASE (N-OXIDE FORMING); FORKHEAD TRANSCRIPTION FACTOR; FOXO1 PROTEIN, MOUSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MESSENGER RNA; OXYGENASE; TRIACYLGLYCEROL;

CARDIOVASCULAR DISEASE; DIABETES; ENZYME ACTIVITY; GENE EXPRESSION; METABOLISM; RODENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; GLUCOSE TOLERANCE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERLIPIDEMIA; IN VITRO STUDY; INSULIN RESISTANCE; MALE; METABOLIC REGULATION; MOUSE; NONHUMAN; PROTEIN EXPRESSION; ANIMAL; DRUG EFFECTS; GENE EXPRESSION PROFILING; GENE SILENCING; GENETICS; LIVER; LIVER CELL; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; RAT; REAL TIME POLYMERASE CHAIN REACTION; SPRAGUE DAWLEY RAT; WESTERN BLOTTING;

MUS;

ANIMALS; ATHEROSCLEROSIS; BLOTTING, WESTERN; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; FORKHEAD BOX PROTEIN O1; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION PROFILING; GENE KNOCKDOWN TECHNIQUES; HEPATOCYTES; HUMANS; HYPERGLYCEMIA; HYPERLIPIDEMIAS; HYPOGLYCEMIC AGENTS; IN VITRO TECHNIQUES; INSULIN; INSULIN RESISTANCE; LIVER; MALE; MICE; OBESITY; OXYGENASES; RATS; RATS, SPRAGUE-DAWLEY; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRIGLYCERIDES;

EID: 84927126803     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms7498     Document Type: Article

References (57)

1. Isomaa, B. et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 24, 683-689 (2001).
2. Grundy, S. M. et al. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 100, 1134-1146 (1999).
3. Cholesterol Treatment Trialists, C. et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170, 000 participants in 26 randomised trials. Lancet 376, 1670-1681 (2010).
4. Ginsberg, H. Statins in cardiometabolic disease: what makes pitavastatin different? Cardiovasc. Diabetol. 12(Suppl 1): S1 (2013).
5. Kahn, R., Buse, J., Ferrannini, E. & Stern, M. The metabolic syndrome: time for a critical appraisal. Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 48, 1684-1699 (2005).
6. Biddinger, S. B. & Kahn, C. R. From mice to men: insights into the insulin resistance syndromes. Annu. Rev. Physiol. 68, 123-158 (2006).
7. Michael, M. D. et al. Loss of insulin signaling in hepatocytes leads to severe insulin resistance and progressive hepatic dysfunction. Mol. Cell 6, 87-97 (2000).
8. Haas, J. T. et al. Hepatic insulin signaling is required for obesity-dependent expression of SREBP-1c mRNA but not for feeding-dependent expression. Cell Metab. 15, 873-884 (2012).
9. Biddinger, S. B. et al. Hepatic insulin resistance directly promotes formation of cholesterol gallstones. Nat.Med. 14, 778-782 (2008).
10. Semple, R. K. et al. Postreceptor insulin resistance contributes to human dyslipidemia and hepatic steatosis. J. Clin. Invest. 119, 315-322 (2009).
11. Biddinger, S. B. et al. Hepatic insulin resistance is sufficient to produce dyslipidemia and susceptibility to atherosclerosis. Cell Metab. 7, 125-134 (2008).
12. Koeth, R. A. et al. Intestinal microbiota metabolism of l-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat. Med. 19, 576-585 (2013).
13. Bennett, B. J. et al. Trimethylamine-N-oxide, a metabolite associated with atherosclerosis, exhibits complex genetic and dietary regulation. Cell Metab. 17, 49-60 (2013).
14. Torrecilla, E. et al. Liver upregulation of genes involved in cortisol production and action is associated with metabolic syndrome in morbidly obese patients. Obes. Surg. 22, 478-486 (2012).
15. Li, X. C. & Zhuo, J. L. Current insights and new perspectives on the roles of hyperglucagonemia in non-insulin-dependent type 2 diabetes. Curr. Hypertens. Rep. 15, 522-530 (2013).
16. Bujalska, I. J., Kumar, S. & Stewart, P. M. Does central obesity reflect "Cushing's disease of the omentum"? Lancet 349, 1210-1213 (1997).
17. Di Dalmazi, G., Pagotto, U., Pasquali, R. & Vicennati, V. Glucocorticoids and type 2 diabetes: from physiology to pathology. J. Nutr. Metab. 2012, 525093 (2012).
18. Haas, J. T. & Biddinger, S. B. Dissecting the role of insulin resistance in the metabolic syndrome. Curr. Opin. Lipidol. 20, 206-210 (2009).
19. Matsumoto, M., Pocai, A., Rossetti, L., Depinho, R. A. & Accili, D. Impaired regulation of hepatic glucose production in mice lacking the forkhead transcription factor Foxo1 in liver. Cell Metab. 6, 208-216 (2007).
20. Warrier, M. et al. The TMAO-generating enzyme flavin monooxygenase 3 is a central regulator of cholesterol balance. Cell Rep. doi:10.1016/j.celrep. 2014.12.036 (2015).
21. Wang, Z. et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 472, 57-63 (2011).
22. Shih, D. M. et al. Flavin containing monooxygenase 3 exerts broad effects on glucose and lipid metabolism and atherosclerosis. J. Lipid Res. 56, 22-37 (2015).
23. Horton, J. D. Sterol regulatory element-binding proteins: transcriptional activators of lipid synthesis. Biochem. Soc. Trans. 30, 1091-1095 (2002).
24. Radhakrishnan, A., Goldstein, J. L., McDonald, J. G. & Brown, M. S. Switch-like control of SREBP-2 transport triggered by small changes in ER cholesterol: a delicate balance. Cell Metab. 8, 512-521 (2008).
25. Miao, J. et al. Hepatic insulin signaling is required for cholesterologenic gene expression. J. Lipid Res. 55, 659-667 (2014).
26. Stittrich, A. B. et al. The microRNA miR-182 is induced by IL-2 and promotes clonal expansion of activated helper T lymphocytes. Nat. Immunol. 11, 1057-1062 (2010).
27. Guttilla, I. K. & White, B. A. Coordinate regulation of FOXO1 by miR-27a, miR-96, and miR-182 in breast cancer cells. J. Biol. Chem. 284, 23204-23216 (2009).
28. Kim, K. M. et al. miR-182 is a negative regulator of osteoblast proliferation, differentiation, and skeletogenesis through targeting FoxO1. J. Bone Mineral Res. 27, 1669-1679 (2012).
29. Jeon, T. I. et al. An SREBP-responsive microRNA operon contributes to a regulatory loop for intracellular lipid homeostasis. Cell Metab. 18, 51-61 (2013).
30. Bennett, M. K., Seo, Y. K., Datta, S., Shin, D. J. & Osborne, T. F. Selective binding of sterol regulatory element-binding protein isoforms and co-regulatory proteins to promoters for lipid metabolic genes in liver. J. Biol. Chem. 283, 15628-15637 (2008).
31. Horton, J. D., Goldstein, J. L. & Brown, M. S. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J. Clin. Invest. 109, 1125-1131 (2002).
32. Strong, A. et al. Hepatic sortilin regulates both apolipoprotein B secretion and LDL catabolism. J. Clin. Invest. 122, 2807-2816 (2012).
33. Zhang, Y. et al. Hepatic expression of scavenger receptor class B type I (SR-BI) is a positive regulator of macrophage reverse cholesterol transport in vivo. J. Clin. Invest. 115, 2870-2874 (2005).
34. Wan, M. et al. Postprandial hepatic lipid metabolism requires signaling through Akt2 independent of the transcription factors FoxA2, FoxO1, and SREBP1c. Cell Metab. 14, 516-527 (2011).
35. Li, Q. et al. Synchronous evolution of an odor biosynthesis pathway and behavioral response. Curr. Biol. 23, 11-20 (2013).
36. Tang, W. H. et al. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N. Engl. J. Med. 368, 1575-1584 (2013).
37. Shih, D. M. et al. Flavin containing monooxygenase 3 exerts broad effects on glucose and lipid metabolism and atherosclerosis. J Lipid Res 56, 22-37 (2015).
38. Gross, D. N., Wan, M. & Birnbaum, M. J. The role of FOXO in the regulation of metabolism. Curr. Diab. Rep. 9, 208-214 (2009).
39. Dong, X. C. et al. Inactivation of hepatic Foxo1 by insulin signaling is required for adaptive nutrient homeostasis and endocrine growth regulation. Cell Metab. 8, 65-76 (2008).
40. Cheng, Z. et al. Foxo1 integrates insulin signaling with mitochondrial function in the liver. Nat. Med. 15, 1307-1311 (2009).
41. Lu, M. et al. Insulin regulates liver metabolism in vivo in the absence of hepatic Akt and Foxo1. Nat. Med. 18, 388-395 (2012).
42. Leavens, K. F., Easton, R. M., Shulman, G. I., Previs, S. F. & Birnbaum, M. J. Akt2 is required for hepatic lipid accumulation in models of insulin resistance. Cell Metab. 10, 405-418 (2009).
43. Gross, D. N., van den Heuvel, A. P. & Birnbaum, M. J. The role of FoxO in the regulation of metabolism. Oncogene 27, 2320-2336 (2008).
44. Kamagate, A. et al. FoxO1 mediates insulin-dependent regulation of hepatic VLDL production in mice. J. Clin. Invest. 118, 2347-2364 (2008).
45. Samuel, V. T. et al. Targeting foxo1 in mice using antisense oligonucleotide improves hepatic and peripheral insulin action. Diabetes 55, 2042-2050 (2006).
46. Zhang, W. et al. FoxO1 regulates multiple metabolic pathways in the liver: effects on gluconeogenic, glycolytic, and lipogenic gene expression. J. Biol. Chem. 281, 10105-10117 (2006).
47. Saxena, R. et al. Genetic variation in GIPR influences the glucose and insulin responses to an oral glucose challenge. Nat. Genet. 42, 142-148 (2010).
48. Guo, S. et al. The Irs1 branch of the insulin signaling cascade plays a dominant role in hepatic nutrient homeostasis. Mol. Cell Biol. 29, 5070-5083 (2009).
49. Roberts, L. D., Souza, A. L., Gerszten, R. E. & Clish, C. B. Curr. Protoc. Mol. Biol. (eds Frederick, M. A. et al.) Chapter 30, Unit 30 32 31-24 (2012).
50. Brown, J. M. et al. Targeted depletion of hepatic ACAT2-driven cholesterol esterification reveals a non-biliary route for fecal neutral sterol loss. J. Biol. Chem. 283, 10522-10534 (2008).
51. Lee, R. G. et al. Plasma cholesteryl esters provided by lecithin:cholesterol acyltransferase and acyl-coenzyme a:cholesterol acyltransferase 2 have opposite atherosclerotic potential. Circ. Res. 95, 998-1004 (2004).
52. Gautier, L., Cope, L., Bolstad, B. M. & Irizarry, R. A. affy-analysis of Affymetrix GeneChip data at the probe level. Bioinformatics 20, 307-315 (2004).
53. Wettenhall, J. M. & Smyth, G. K. limmaGUI: a graphical user interface for linear modeling of microarray data. Bioinformatics 20, 3705-3706 (2004).
54. Rhee, E. P. et al. Lipid profiling identifies a triacylglycerol signature of insulin resistance and improves diabetes prediction in humans. J. Clin. Invest. 121, 1402-1411 (2011).
55. Reich, M. et al. GenePattern 2.0. Nat. Genet. 38, 500-501 (2006).
56. Chen, G., Liang, G., Ou, J., Goldstein, J. L. & Brown, M. S. Central role for liver X receptor in insulin-mediated activation of Srebp-1c transcription and stimulation of fatty acid synthesis in liver. Proc. Natl Acad. Sci. USA 101, 11245-11250 (2004).
57. Dirlam, K. A., Gretch, D. G., LaCount, D. J., Sturley, S. L. & Attie, A. D. Expression and characterization of a truncated, soluble, low-density lipoprotein receptor. Protein Expr. Purif. 8, 489-500 (1996).